This study found that HIV-1 could be eliminated in mice using a combination of two antiviral technologies—long-acting viral reservoir–targeted antiretroviral therapy and CRISPR/Cas-9 gene editing. HIV was undetectable in 9 out of 23 mice that received the combination treatment. HIV was not eliminated in any of the mice that were given either treatment alone.
The dopamine D3 receptor antagonist VK4-116 reduced oxycodone self-administration in rats, as well as drug-seeking behaviors after oxycodone reinstatement following withdrawal. VK4-116 did not interfere with oxycodone’s pain-relieving effects
In animal studies, α2δ-1 and its interactions with NMDA receptors in the spinal cord triggered the pain sensitivity and analgesic tolerance that occurs with chronic morphine treatment. Blocking the α2δ-1–NMDA interaction reduced opioid-induced hyperalgesia and analgesic tolerance.
Mindful Awareness in Body-Oriented Therapy (MABT) improved emotion regulation, reduced craving, and promoted abstinence in women with a history of trauma and emotional problems receiving outpatient treatment for substance use disorder.
This study showed that rats will forgo heroin and methamphetamine in favor of spending time with another rat. It also highlights the importance of incorporating voluntary choice between drugs and social rewards in drug addiction research.
Interim treatment with buprenorphine significantly improved the psychiatric symptoms of people awaiting comprehensive treatment for opioid use disorder (OUD). Buprenorphine treatment, even without concurrent psychosocial counseling, may help patients with no, or delayed, access to comprehensive OUD treatment.
Smokers who switch to cigarettes with very low nicotine content may experience mild and transient increases in some withdrawal symptoms. Cigarettes with reduced nicotine will be easier to quit than the cigarettes marketed at present.
A clinical trial found that patients who self-administered cognitive behavioral therapy (CBT) using computerized training modules reduced their drug use as much as patients who received clinician-delivered CBT, and they maintained this advantage through a 6-month follow-up.
In the final installment of this series, Dr. Diana Martinez navigates the process for receiving NIH funding to test the efficacy of using transcranial magnetic stimulation as treatment for cocaine addiction.
In two pilot clinical trials, buprenorphine helped participants reduce their illicit opioid use and injection drug use while awaiting admission to a methadone or buprenorphine treatment program. Researchers minimized the risks for improper use or diversion of the study medication by giving it to trial participants in a computerized, tamper-proof device that dispenses one dose each day.
Patients who received transcranial magnetic stimulation (TMS) were more likely to abstain from cocaine than patients who received medications for symptoms associated with abstinence. Researchers concluded that TMS appears to be safe and its efficacy as a treatment for cocaine addiction deserves to be evaluated in a larger clinical trial.
Patients who don’t take their medications as prescribed often put themselves at risk for problems including misdiagnoses, complications, and death. A study suggests that adding low doses of quinine to patients’ medications could provide an inexpensive, reliable, and safe method of monitoring whether patients are taking their medications as directed.
Treatment with an extended-release stimulant medication plus cognitive behavioral therapy was associated with reductions in cocaine use and in attention-deficit/hyperactivity disorder symptoms in patients with both disorders.
During investigations into using transcranial brain stimulation (TMS) to treat cocaine abuse, two projects take diverging paths. One researcher moves to the next stage, while another is forced to cut his trial short.
Treatment that combines use of Bp/Nx and memantine may enable young adults addicted to opioids establish lasting abstinence after a relatively brief course of medication-assisted therapy, a pilot trial suggests.